Binimetinib
Binimetinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Malignant Solid Neoplasm、Anatomic Stage III Breast Cancer AJCC v8、Anatomic Stage IV Breast Cancer AJCC v8、Locally Advanced Malignant Solid Neoplasm。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
19 项
全球在招研究
2 项
已进入 III/IV 期
22 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- UNICANCER
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- University of California, San Francisco
- Nationwide Children's Hospital
- Rina Plattner
- Grupo Español Multidisciplinar de Melanoma
- Pierre Fabre Pharma GmbH
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
比利时、法国、英国、西班牙、美国、澳大利亚、加拿大、奥地利、德国、瑞士、日本、Puerto Rico
正在招募患者的 Binimetinib 研究
Personalized Medicine for Advanced Biliary Cancer Patients
III 期招募中比利时法国英国NCT05615818Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer
II 期招募中西班牙NCT06207656Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
II 期招募中美国NCT04598009Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
II 期招募中美国NCT04322383MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
II 期招募中美国澳大利亚加拿大NCT05286788Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
I 期招募中美国NCT04903119Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
II 期招募中西班牙NCT06887088Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
不适用招募中奥地利德国瑞士NCT04045691Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
II 期招募中日本NCT06159478Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
II 期招募中美国Puerto RicoNCT05564377Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
I 期招募中美国NCT05111561Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
不适用招募中法国NCT06774989A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
I 期招募中美国澳大利亚中国法国NCT04913285Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
II 期招募中美国NCT05026983Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
早期 I 期招募中美国NCT04741997Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
I 期 / II 期招募中美国澳大利亚加拿大NCT03947385A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
II 期招募中美国NCT04511013The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
IV 期招募中美国澳大利亚Brazil加拿大NCT05203172Melanoma Metastasized to the Brain and Steroids
II 期招募中丹麦NCT03563729
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。